← feed

Is NCT03327558 results overdue?

Yes — results are overdue. Primary completion was 2017-06-23; the FDAAA-801 reporting deadline (2018-06-23) passed 2920 days ago and no results are posted on ClinicalTrials.gov.

Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects

NCT IDNCT03327558 ↗
SponsorBausch Health Americas, Inc. (INDUSTRY)
Public issuerBausch Health Companies Inc. — BHC (CIK 0000885590) best-effort name match, 82% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-06-23 (ACTUAL)
Reporting deadline2018-06-23 (completion + 365d)
Days overdue2920
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 96aa08762644d8e5… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03327558. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →